- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Digital rectal examination not useful for screening prostate cancer in young men
A digital rectal exam is a diagnostic tool for many medical issues like Inflammatory bowel disease, Hemorrhoids, Prostate infection, prostate cancer, rectal or colon cancer, and other disorders. A recent study published in European Urology Oncology has demonstrated the poor diagnostic performance of digital rectal examination prostate cancer (PCa) screening in young men.
In Germany, For screening of PCa, Annual DRE is recommended as a stand-alone screening test in 45+ yr olds. The diagnostic performance of DRE in men as young as 45 is not proved by a screening trial. The main objective of the present study is to determine DRE diagnostic performance in analysis conducted within the multicentric, randomized PROBASE trial.
The study enrolled > 46,000 men at age 45 to test risk-adapted prostate-specific antigen (PSA) screening for PCa. The intervention included DRE analyses as a one-time, stand-alone screening offer at age 45 in 6537 men in one arm of the trial and evaluation of PCa detection by DRE at the time of PSA-screen–driven biopsies (N = 578).
The Outcome measurements and statistical analysis included True-/false-positive detection rates of DRE than PSA screening and evaluation of DRE outcome at the time of a prostate biopsy.
The key findings of the study are:
- A prospective analysis of 57 men with suspicious DRE at age 45 revealed three PCa.
- The rate of Detection by DRE was 0.05% (three of 6537) compared to a four-fold higher rate by PSA screening (48 /23 301, 0.21%).
- The true-positive detection rate by DRE relative to screening by PSA was 0.22.
- The false-positive detection rate by DRE was 2.2.
- Among PSA-screen–detected PCa cases, 86% had unsuspicious DRE. The sensitivity relative to PSA was 14%.
- 86 % of these tumours were located in the potentially accessible zones of the prostate, as seen by MRI.
Researchers from the German Cancer Research Center said, “In our study, we found that performance of stand-alone DRE for Prostate cancer screening is poor.”
They mentioned in young men, DRE should not be recommended as a PCa screening test. Furthermore, DRE does not improve the detection of PSA-screen–detected PCa.
Reference:
Krilavičiūtė, A., Becker, N., Lakes, J., Radtke, J. P., Kuczyk, M. A., Peters, I., Harke, N., Debus, J., Koerber, S. A., Herkommer, K., Gschwend, J. E., Meissner, V. H., Benner, A., Seibold, P., Kristiansen, G., Hadaschik, B., Arsov, C., Schimmöller, L., Giesel, F. L., . . . Albers, P. (2023). Digital rectal examination is not a useful screening test for prostate cancer. European Urology Oncology. https://doi.org/10.1016/j.euo.2023.09.008
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751